A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study
Year: 2011
Type: article
Study design: Clinical Trial
Authors: Joseph Chao, Timothy W. Synold, Robert J. Morgan, Charles Kunos, Jeff Longmate, Heinz-Josef Lenz, Dean Lim, Stephen Shibata, Vincent Chung, Ronald G. Stoller, Chandra P. Belani, David R. Gandara, Mark McNamara, Barbara J. Gitlitz, Derick H. Lau, Suresh S. Ramalingam, Angela Davies, Igor Espinoza-Delgado, Edward M. Newman, Yun Yen
Institutions: City Of Hope National Medical Center, City of Hope, Case Western Reserve University, University of Southern California, USC Norris Comprehensive Cancer Center, UPMC Hillman Cancer Center, Penn State Cancer Institute, UC Davis Comprehensive Cancer Center, University of California, Davis, Winship Cancer Institute, National Institutes of Health, National Cancer Institute
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: green
Awards: G2713903917, Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis, Southern California Clinical and Translational Science Institute, University of Pittsburgh Clinical and Translational Science Institute, G422284981, Phase I Molecular and Clincal Pharmacodynamic Trials, G571758621, G639072624, G661928818, G772794905, G830266829, G884570035
OpenAlex ID: W2149078186